Physician profile
Edie Willis
NPI 1356877328
$14,148.64
in general payments reported to CMS, 2019-2025
27 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,262 · 2022: $9,845 · 2023: $1,919 · 2024: $13.32 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,805 · Food and Beverage: $1,216 · Education: $20.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,805.00 |
| Food and Beverage | $1,216.02 |
| Education | $20.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $10,605.13 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $600.62 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $541.71 | 2021-2025 | Farxiga, Lokelma, Evusheld |
| Otsuka America Pharmaceutical, INC. | $354.08 | 2021-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $302.52 | 2021-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $210.39 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $179.37 | 2021-2022 | |
| Averitas Pharma INC. | $157.27 | 2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $134.24 | 2021 | |
| Amgen INC. | $122.96 | 2021-2025 | Krystexxa |
| Lilly USA, LLC | $118.45 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $117.95 | 2021-2025 | Wegovy |
| Travere Therapeutics, INC. | $101.45 | 2022-2025 | Filspari |
| Fresenius USA Marketing, INC. | $94.90 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $94.37 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $73.89 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $63.83 | 2021-2025 | Shingrix, Arexvy |
| Ardelyx, INC. | $58.24 | 2025 | Ibsrela |
| Cormedix INC. | $37.50 | 2025 | Defencath |
| Genzyme Corporation | $34.33 | 2022 | |
| Calliditas Therapeutics US INC. | $30.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.78 | 2021 | |
| Pfizer INC. | $23.33 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.74 | 2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $19.03 | 2021 | |
| Philips North America LLC | $13.32 | 2024 | (Am5) Lead Management |
| Akebia Therapeutics INC | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edie Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.